371 related articles for article (PubMed ID: 28928091)
21. Response variability to P2Y12 receptor inhibitors: expectations and reality.
Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
JACC Cardiovasc Interv; 2013 Nov; 6(11):1111-28. PubMed ID: 24262612
[TBL] [Abstract][Full Text] [Related]
22. Salvianolic acid B inhibits platelets as a P2Y12 antagonist and PDE inhibitor: evidence from clinic to laboratory.
Liu L; Li J; Zhang Y; Zhang S; Ye J; Wen Z; Ding J; Kunapuli SP; Luo X; Ding Z
Thromb Res; 2014 Oct; 134(4):866-76. PubMed ID: 25077998
[TBL] [Abstract][Full Text] [Related]
23. Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.
Tan GM; Lam YY; Yan BP
Cardiovasc Ther; 2012 Aug; 30(4):e167-73. PubMed ID: 21883998
[TBL] [Abstract][Full Text] [Related]
24. Platelets Express Activated P2Y
Hu L; Chang L; Zhang Y; Zhai L; Zhang S; Qi Z; Yan H; Yan Y; Luo X; Zhang S; Wang Y; Kunapuli SP; Ye H; Ding Z
Circulation; 2017 Aug; 136(9):817-833. PubMed ID: 28637879
[TBL] [Abstract][Full Text] [Related]
25. Role of Platelet Transfusion in the Reversal of Anti-Platelet Therapy.
Nagalla S; Sarode R
Transfus Med Rev; 2019 Apr; 33(2):92-97. PubMed ID: 30814031
[TBL] [Abstract][Full Text] [Related]
26. Signaling via P2Y12 may be critical for early stabilization of platelet aggregates.
Speich HE; Bhal V; Houser KH; Caughran AT; Lands LT; Houng AK; Bäckstrom J; Enerbäck M; Reed GL; Jennings LK
J Cardiovasc Pharmacol; 2014 Jun; 63(6):520-7. PubMed ID: 24477045
[TBL] [Abstract][Full Text] [Related]
27. Evidence of platelet activation at medically used hypothermia and mechanistic data indicating ADP as a key mediator and therapeutic target.
Straub A; Krajewski S; Hohmann JD; Westein E; Jia F; Bassler N; Selan C; Kurz J; Wendel HP; Dezfouli S; Yuan Y; Nandurkar H; Jackson S; Hickey MJ; Peter K
Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1607-16. PubMed ID: 21512161
[TBL] [Abstract][Full Text] [Related]
28. Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro: Insights using short thromboelastography.
Khanna V; Armstrong PC; Warner TD; Curzen N
Platelets; 2015; 26(7):689-92. PubMed ID: 25734957
[TBL] [Abstract][Full Text] [Related]
29. The role of ADP receptors in platelet function.
Murugappa S; Kunapuli SP
Front Biosci; 2006 May; 11():1977-86. PubMed ID: 16368572
[TBL] [Abstract][Full Text] [Related]
30. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
31. Pharmacodynamic interplay of the P2Y(1), P2Y(12), and TxA(2) pathways in platelets: the potential of triple antiplatelet therapy with P2Y(1) receptor antagonism.
Oestreich JH; Ferraris SP; Steinhubl SR; Akers WS
Thromb Res; 2013 Feb; 131(2):e64-70. PubMed ID: 23245937
[TBL] [Abstract][Full Text] [Related]
32. Use of antiplatelet agents in sepsis: a glimpse into the future.
Akinosoglou K; Alexopoulos D
Thromb Res; 2014 Feb; 133(2):131-8. PubMed ID: 24103487
[TBL] [Abstract][Full Text] [Related]
33. P2Y12 Receptor Modulates Sepsis-Induced Inflammation.
Liverani E; Rico MC; Tsygankov AY; Kilpatrick LE; Kunapuli SP
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):961-71. PubMed ID: 27055904
[TBL] [Abstract][Full Text] [Related]
34. Loss of P2Y
Paul DS; Blatt TN; Schug WJ; Clark EG; Kawano T; Mackman N; Murcia S; Poe KO; Mwiza JMN; Harden TK; Bergmeier W; Nicholas RA
J Thromb Haemost; 2023 Jul; 21(7):1891-1902. PubMed ID: 36958516
[TBL] [Abstract][Full Text] [Related]
35. BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y12 antagonism.
Zhang S; Hu L; Du H; Guo Y; Zhang Y; Niu H; Jin J; Zhang J; Liu J; Zhang X; Kunapuli SP; Ding Z
Thromb Haemost; 2010 Oct; 104(4):845-57. PubMed ID: 20806121
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model.
Ravnefjord A; Weilitz J; Emanuelsson BM; van Giezen JJ
Thromb Res; 2012 Oct; 130(4):622-8. PubMed ID: 22909827
[TBL] [Abstract][Full Text] [Related]
37. Can the antiplatelet effects of cangrelor be reliably studied in mice under in vivo and in vitro conditions using flow cytometry?
Kassassir H; Siewiera K; Sychowski R; Watała C
Pharmacol Rep; 2013; 65(4):870-83. PubMed ID: 24145081
[TBL] [Abstract][Full Text] [Related]
38. Anti-platelet and anti-thrombogenic effects of shikimic acid in sedentary population.
Veach D; Hosking H; Thompson K; Santhakumar AB
Food Funct; 2016 Aug; 7(8):3609-16. PubMed ID: 27480079
[TBL] [Abstract][Full Text] [Related]
39. A comparison of different regression models for the quantitative analysis of the combined effect of P2Y
Watala C; Wzorek J; Palma A; Boncler M
Thromb Res; 2022 Mar; 211():88-97. PubMed ID: 35134667
[TBL] [Abstract][Full Text] [Related]
40. Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y(12) antagonism.
Jakubowski JA; Zhou C; Egan B; Wells M; Kotob-Yahfoufi M; Sugidachi A; Dahlen JR
Platelets; 2011; 22(8):619-25. PubMed ID: 21639823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
